Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma

International Journal of Hematology

Volumn 74, Issue 2, 2001, Pages 205-208

  Shimizu, Kazuyuki ^a   Nagura, Eiichi ^b   Hirabayashi, Noriyuki ^c   Wakita, Atsushi ^d   Takeyama, Hideo ^e   Sao, Hiroshi ^f   Nitta, Masakazu ^g   Kawashima, Kohei ^h   Saito, Hidehiko ^h  

^a Nagoya City Higashi General Hospital   (Japan)

^b CHUBU NATIONAL HOSPITAL   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^d NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^e Nagoya Ekisaikai Hospital   (Japan)

^f Meitetsu Hospital   (Japan)

^g AICHI MEDICAL UNIVERSITY   (Japan)

^h NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

M protein nadir; Multiple myeloma; Percent reduction; Plateau attainment; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MULTIPLE MYELOMA M PROTEINS; MULTIPLE MYELOMA M-PROTEINS; PARAPROTEIN; TUMOR MARKER;

ARTICLE; BLOOD; HUMAN; MORTALITY; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MULTIPLE MYELOMA; MYELOMA PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0035431468     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982006     Document Type: Article

References (8)

1. Joshua DE, Snowdon L, Gibson J, et al. Multiple myeloma: Plateau phase revisited. Hematol Rev. 1991;5:59-66.
2. Oivanen TM. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Brit J Haematol. 1996;92: 834-839.
3. Durie BGM, Russell DH, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet. 1980;2:65-68.
4. Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.
5. Chronic Leukemia-Myeloma Task Force. Proposed guidelines for protocol studies. II: Plasma cell myeloma. Cancer Treat Rep. 1973;4: 145-158.
6. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1966;53:457-481.
7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50: 165-170.
8. Gehan E. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203-223.